News Detail

This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Benzinga · 01/21 13:49

Listen to the news

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Citizens analyst James McCanless initiated coverage on Century Communities Inc (NYSE:CCS) with a Market Outperform rating and announced a price target of $92. Century Communities shares closed at $66.26 on Tuesday. See how other analysts view this stock.
Chardan Capital analyst Janani Sundararajan initiated coverage on Alumis Inc (NASDAQ:ALMS) with a Buy rating and announced a price target of $37. Alumis shares closed at $26.06 on Tuesday. See how other analysts view this stock.
Rosenblatt analyst Mike Genovese initiated coverage on Credo Technology Group Holding Ltd (NASDAQ:CRDO) with a Neutral rating and announced a price target of $170. Credo Technology shares closed at $153.22 on Tuesday. See how other analysts view this stock.
Guggenheim analyst Brad Canino initiated coverage on Crescent Biopharma Inc (NASDAQ:CBIO) with a Buy rating and announced a price target of $35. Crescent Biopharma shares closed at $13.98 on Tuesday. See how other analysts view this stock.
Ladenburg Thalmann analyst Jon Hickman initiated coverage on Amaze Holdings Inc (AMEX:AMZE) with a Buy rating and announced a price target of $3. Amaze Holdings shares closed at $0.42 on Tuesday. See how other analysts view this stock.

Considering buying CBIO stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.